Liegl Bernadette, Hornick Jason L, Lazar Alexander J F
Department of Pathology, Medical University of Graz, Auenbruggerplatz 25, A 8036 Graz, Austria.
Hematol Oncol Clin North Am. 2009 Feb;23(1):49-68, vii-viii. doi: 10.1016/j.hoc.2008.12.002.
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. The vast majority of GISTs harbor a KIT or PDGFRA mutation and express KIT by immunohistochemistry. However, KIT-negative tumors and tumors showing unusual morphologic features can cause major diagnostic problems. The ability to inhibit the active KIT or PDGFRA kinase with tyrosine kinase inhibitors and alternative drugs demands more than ever accurate tumor classification and risk assessment. This article focuses on the pathology of GIST, including unusual variants and morphologic changes resulting from treatment. Parameters for risk assessment, potentially helpful new immunohistochemical markers, differential diagnosis, and the application of molecular classification schemes are discussed.
胃肠道间质瘤(GISTs)是胃肠道最常见的间叶性肿瘤。绝大多数GISTs存在KIT或PDGFRA突变,并通过免疫组织化学表达KIT。然而,KIT阴性肿瘤和具有不寻常形态特征的肿瘤会导致重大诊断问题。用酪氨酸激酶抑制剂和替代药物抑制活性KIT或PDGFRA激酶的能力比以往任何时候都更需要准确的肿瘤分类和风险评估。本文重点关注GIST的病理学,包括不寻常的变体和治疗引起的形态学变化。讨论了风险评估参数、潜在有用的新免疫组织化学标志物、鉴别诊断以及分子分类方案的应用。